Clinical implication and risk factor of pneumonia development in mild coronavirus disease 2019 patients
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Although a majority of coronavirus disease 2019 (COVID-19) cases were characterized as mild, data assessing the development of pneumonia in mild COVID-19 patients are limited. We aimed to examine the effect of pneumonia development on the clinical course of mild COVID-19 in hospitalized patients. Methods: A retrospective cohort study was conducted via medical record review between February 25, 2020 and April 11, 2020 at a single center. The impact of pneumonia development on the time to viral clearance in mild COVID-19 patients was evaluated. Risk factors associated with the development of pneumonia were also identified. Results: Chest radiographs revealed the development of pneumonia in 26.8% of mild COVID-19 patients. The time to pneumonia development was a median of 8.0 days from the onset of symptoms and 3.5 days after hospital admission. A multivariate analysis for predicting pneumonia development identified age ≥ 65 years (odds ratio [OR], 3.15; 95% confidence interval [CI], 1.14 to 8.73), cough (OR, 2.18; 95% CI, 1.29 to 3.68), dyspnea (OR, 3.58; 95% CI, 1.10 to 11.69), and diarrhea (OR, 2.69; 95% CI, 1.51 to 4.78) as significant variables. The time to negative conversion was longer in mild COVID-19 patients who developed pneumonia (23.6 days vs. 18.4 days, p = 0.003). In Kaplan–Meier estimation and multivariate Cox regression analyses, newly developed pneumonia was significantly related with delayed time to negative conversion (log-rank test, p = 0.02; hazard ratio, 2.90; 95% CI, 1.06 to 7.97). Conclusions: The development of pneumonia delayed viral clearance in patients with mild COVID-19. Elderly patients or those suffering from diarrhea should be closely monitored, given the increased risk of developing pneumonia.
Abstract
Background/Aims: Although a majority of coronavirus disease 2019 (COVID-19) cases were characterized as mild, data assessing the development of pneumonia in mild COVID-19 patients are limited. We aimed to examine the effect of pneumonia development on the clinical course of mild COVID-19 in hospitalized patients. Methods: A retrospective cohort study was conducted via medical record review between February 25, 2020 and April 11, 2020 at a single center. The impact of pneumonia development on the time to viral clearance in mild COVID-19 patients was evaluated. Risk factors associated with the development of pneumonia were also identified. Results: Chest radiographs revealed the development of pneumonia in 26.8% of mild COVID-19 patients. The time to pneumonia development was a median of 8.0 days from the onset of symptoms and 3.5 days after hospital admission. A multivariate analysis for predicting pneumonia development identified age ≥ 65 years (odds ratio [OR], 3.15; 95% confidence interval [CI], 1.14 to 8.73), cough (OR, 2.18; 95% CI, 1.29 to 3.68), dyspnea (OR, 3.58; 95% CI, 1.10 to 11.69), and diarrhea (OR, 2.69; 95% CI, 1.51 to 4.78) as significant variables. The time to negative conversion was longer in mild COVID-19 patients who developed pneumonia (23.6 days vs. 18.4 days, p = 0.003). In Kaplan–Meier estimation and multivariate Cox regression analyses, newly developed pneumonia was significantly related with delayed time to negative conversion (log-rank test, p = 0.02; hazard ratio, 2.90; 95% CI, 1.06 to 7.97). Conclusions: The development of pneumonia delayed viral clearance in patients with mild COVID-19. Elderly patients or those suffering from diarrhea should be closely monitored, given the increased risk of developing pneumonia.
참고문헌 (29)
- "WHO coronavirus disease (COVID-19) dashboard" (2020)[URL]
- Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
- Ruan Q, "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China", Intensive Care Med, 46, pp.846~848 (2020)
- Ji D, "Prediction for progression risk in patients with COVID-19 pneumonia : the CALL Score", Clin Infect Dis, 71, pp.1393~1399 (2020)
- Du RH, "Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2 : a prospective cohort study", Eur Respir J, 55, pp.2000524~ (2020)
- Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
- Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descriptive study", Lancet, 395, pp.507~513 (2020)
- Chan JF, "A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission : a study of a family cluster", Lancet, 395, pp.514~523 (2020)
- Gandhi RT, "Mild or moderate Covid-19", N Engl J Med, 383, pp.1757~1766 (2020)
- "Interim guidance for implementing home care of people not requiring hospitalization for coronavirus disease 2019(COVID-19)" (2020)[URL]
- Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China", JAMA Intern Med, 180, pp.934~943 (2020)
- Nakamura K, "A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan : a case report", J Infect Chemother, 26, pp.756~761 (2020)
- Zhan WQ, "Successful treatment of COVID-19 using extracorporeal membrane oxygenation, a case report", Eur Rev Med Pharmacol Sci, 24, pp.3385~3389 (2020)
- Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
- von Elm E, "The Strengthening the Reporting of Observational Studies in Epidemiology(STROBE)Statement : guidelines for reporting observational studies", Int J Surg, 12, pp.1495~1499 (2014)
- WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection, "A minimal common outcome measure set for COVID-19 clinical research", Lancet Infect Dis, 20, pp.e192~ (2020)
- Leung WK, "Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection", Gastroenterology, 125, pp.1011~1017 (2003)
- Assiri A, "Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia : a descriptive study", Lancet Infect Dis, 13, pp.752~761 (2013)
- Jin X, "Epidemiological, clinical and virological characteristics of 74 cases of coronavirusinfected disease 2019(COVID-19)with gastrointestinal symptoms", Gut, 69, pp.1002~1009 (2020)
- Gao QY, "2019 Novel coronavirus infection and gastrointestinal tract", J Dig Dis, 21, pp.125~126 (2020)
- Jing QL, "household secondary attack rate of COVID-19 and associated determinants", medRxiv 2020 Apr 15. https:, doi.org, pp.10.1101, 2020.04.11.20056010[DOI]
- Chen J, "Clinical progression of patients with COVID-19 in Shanghai, China", J Infect, 80, pp.e1~e6 (2020)
- Liu Y, "Viral dynamics in mild and severe cases of COVID-19", Lancet Infect Dis, 20, pp.656~657 (2020)
- Hu X, "Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19", Sci Total Environ, 728, pp.138812~ (2020)
- Bernheim A, "Chest CT findings in coronavirus disease-19(COVID-19) : relationship to duration of infection", Radiology, 295, pp.200463~ (2020)
- Toussie D, "Clinical and chest radiography features determine patient outcomes in young and middle-aged adults with COVID-19", Radiology, 297, pp.E197~E206 (2020)
- Wong HYF, "Frequency and distribution of chest radiographic findings in patients positive for COVID-19", Radiology, 296, pp.E72~E78 (2020)
- Ng MY, "Imaging profile of the COVID-19 infection : radiologic findings and literature review", Radiol Cardiothorac Imaging, 2, pp.e200034~ (2020)